StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $7.91 | $7.73 | -2.28% | 0.0M |
| 05-12 | $7.73 | $7.73 | +0.00% | 0.0M |
| 05-13 | $7.90 | $7.76 | -1.77% | 0.0M |
| 05-14 | $7.74 | $8.81 | +13.82% | 0.7M |
| 05-15 | $8.80 | $8.36 | -5.00% | 0.0M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $12.65M | $43.77M | $30.08M | $11.01M |
Operating Income | $-14.11M | $-41.98M | $-30.15M | $-28.22M |
Net Income | $-9.53M | $-35.04M | $-45.40M | $-29.11M |
EPS (Diluted) | $-0.58 | $-4.19 | $-0.43 | $-0.34 |
Total Assets | $163.49M | $154.69M | $133.69M | $133.81M |
Total Liabilities | $90.94M | $119.41M | $141.79M | $126.74M |
Cash & Equivalents | $150.33M | $137.53M | $103.76M | $121.55M |
Free Cash Flow OCF − CapEx | $-22.90M | $-5.51M | $-3.42M | $14.08M |
Shares Outstanding | 5.78M | 4.53M | 51.83M | 51.83M |
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.